Compare Organon & Co. Common Stock (OGN) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Trade Desk Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Trade Desk Inc trades at $12.11 (market cap $5.75B). The key difference: Trade Desk Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Trade Desk Inc for 73 Days on average.
| OGN | TTD | |
|---|---|---|
Market Cap | $3.62B | $5.75B |
Volume | 2,892,999 | 15,249,283 |
Sector | Health | Media |
52-Week High | $13.81 | $54.13 |
52-Week Low | $5.70 | $11.92 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $11.04B | $4.70B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
The Trade Desk (TTD) trades at $12.17, down 68% year-to-date amid a bearish technical outlook and slowing revenue growth. Recent earnings show mixed results with a Q2 beat but a Q1 miss, while Q3 2026 guidance indicates a 12% revenue decline. The company maintains strong profitability margins and a low P/E ratio, but faces intense competition from tech giants and has announced workforce reductions.
The stock presents a high-risk opportunity with a consensus price target of $14.68 offering potential upside, though near-term headwinds from competition and index removal flows persist. Long-term prospects hinge on the company's ability to defend its open internet ad platform against Amazon and Google while restoring growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
